tirzepatide chronic kidney disease trial Tirzepatide Shows Kidney Benefits in T2D: SURPASS Trials Analysis

At #ACC25, Dr. Milton Packer and colleagues present a new secondary analysis from the SUMMIT trial evaluating the effect of tirzepatide in patients with obesity, #HFpEF, and CKD. The trial demonstrated that #

29.85

★★★★☆4.8 (126)

CONFIDENCE trial: In persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone

22.04

★★★★★4.9 (98)

Tirzepatide Demonstrates Remarkable Kidney Protection in Type 2 Diabetes Patients Compared to Dulaglutide

20.07

★★★★★5.0 (157)

Tirzepatide (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https

22.05

★★★★★4.7 (84)

An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

25.10

★★★★★4.9 (203)

Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study

20.94

★★★★★5.0 (176)

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

22.90

★★★★★4.8 (132)